Daiichi Sankyo has signed a contract with Hitachi Chemical to manufacture investigational cell products derived from iPS or somatic cells at Hitachi Kazei’s Yamazaki Plant in Yokohama. Hitachi Chemical formed in May 2017 in the US a a wholly-owned subsidiary, Hitachi Chemical Advanced Therapeutics Solutions, LLC, one of the largest US companies in the field of consigned manufacturing of regenerative medicines and other products. In April 2018, will start operation of one of Japan's largest contract manufacturing facilities in Yamazaki, and gradually expand its contract manufacturing business for regenerative medicine products in Europe and the United States.
Source: Hitachi Kasei news release, March 19, 2018
Request a quote for deeper information from